

1 **Age- and disease severity-associated changes in the nasopharyngeal microbiota of COVID-**  
2 **19 patients**

3

4 Fernando Pérez-Sanz<sup>1</sup>, Sylwia D. Tyrkalska<sup>1,2,3</sup>, Carmen Álvarez-Santacruz<sup>4</sup>, Antonio Moreno-  
5 Docón<sup>5</sup>, Victoriano Mulero<sup>1,2,3,\*</sup>, María L. Cayuela<sup>1,3,6,\*</sup>, Sergio Candel<sup>1,2,3,\*,&</sup>

6

7 <sup>1</sup>Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, 30120 Murcia, Spain.

8 <sup>2</sup>Grupo de Inmunidad, Inflamación y Cáncer, Departamento de Biología Celular e Histología,  
9 Facultad de Biología, Universidad de Murcia, 30100 Murcia, Spain.

10 <sup>3</sup>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de  
11 Salud Carlos III, 28029 Madrid, Spain.

12 <sup>4</sup>Servicio de Otorrinolaringología, Hospital de la Vega Lorenzo Guirao, 30530 Cieza, Murcia,  
13 Spain.

14 <sup>5</sup>Servicio de Microbiología, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia,  
15 Spain.

16 <sup>6</sup>Grupo de Telomerasa, Cáncer y Envejecimiento, Servicio de Cirugía, Hospital Clínico  
17 Universitario Virgen de la Arrixaca, 30120 Murcia, Spain.

18

19 \*To whom correspondence should be sent at: [vmulero@um.es](mailto:vmulero@um.es) (VM), [marial.cayuela@carm.es](mailto:marial.cayuela@carm.es)  
20 (MLC), [scandel@um.es](mailto:scandel@um.es) (SC).

21 &Lead contact.

22

23

24

1 **ABSTRACT**

2 Dysbiosis has been linked to the pathogenesis of multiple diseases. Although dozens of  
3 publications have associated changes in the nasopharyngeal microbiota to patient's susceptibility  
4 to COVID-19, results from these studies are highly variable and contradictory in many cases.  
5 Addressing the limitations in previous research responsible for that variability, this study uses 16S  
6 rRNA gene sequencing to analyse the nasopharyngeal microbiota of 395 subjects, 117 uninfected  
7 controls and 278 COVID-19 patients, of different age groups that cover the entire lifespan and  
8 across varying disease severities. Importantly, our results reveal that bacterial diversity decreases  
9 progressively throughout life but only in severely ill COVID-19 patients, in whose nasopharynx,  
10 moreover, the opportunistic pathogen bacterial genera *Staphylococcus*, *Corynebacterium*,  
11 *Streptococcus*, *Prevotella*, *Acinetobacter*, and *Pseudomonas* are overrepresented. Notably,  
12 *Scardovia wiggsiae* appears only in severe COVID-19 patients over 60 years of age, suggesting a  
13 potential utility of this bacterial species as a COVID-19 severity biomarker in the elderly, who are  
14 the most susceptible individuals to suffer from serious forms of the disease and the age group that  
15 presents more differences in comparison with the other age groups according to the majority of  
16 the parameters analysed in this study. Our results provide valuable insights into age-associated  
17 dynamics within nasopharyngeal microbiota during severe COVID-19, offering potential avenues  
18 for further exploration and therapeutic interventions.

19

20 **Keywords:** nasopharyngeal microbiome, age differences, COVID-19 severity differences, aging,  
21 human microbiome, 16s rRNA sequencing

22

23

24

25

26

27

28

## 1 BACKGROUND

2 The coronavirus disease 2019 (COVID-19) is caused by the novel betacoronavirus severe  
3 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1), that penetrates the host through the  
4 upper airways (2). The COVID-19 outbreak, declared as a global pandemic by the World Health  
5 Organization on March 11, 2020 (3), has afflicted humans since its inception and continues to take  
6 a huge toll on human life and health, with almost 7 million deaths to date (<https://covid19.who.int/>  
7 Accessed on November 16, 2023). Despite the striking efficacy that COVID-19 vaccines have  
8 shown so far (4, 5), the limited effectiveness of other treatments and the possibility of new variants  
9 emerging that circumvent the protection of such vaccines, requires a deeper knowledge of COVID-  
10 19 pathogenesis as well as the factors that make some human groups more susceptible to the  
11 disease, such as the elderly (6).

12 Among the different parts of the human upper respiratory tract, the nasopharynx is  
13 anatomically unique as it presents a common meeting place for the ear, nose, and mouth cavities  
14 (7). Because of this, nasopharyngeal epithelium plays a crucial role as a portal for initial infection  
15 and transmission of infectious droplet or aerosol-transmitted microorganisms, such as SARS-CoV-  
16 2 as demonstrated by the fact that nasopharyngeal swabs present higher viral loads than nasal (8),  
17 oropharyngeal (9), or throat (10) swabs. Thus, the study of the involvement of the nasopharynx in  
18 health and disease has gained a special prominence since the outbreak of the COVID-19 pandemic  
19 (11), and nasopharyngeal swabs are considered “gold standard” for the diagnosis of SARS-CoV-  
20 2 infections (8).

21 Microorganisms have been found to be part of the microbiota in the different locations of  
22 the healthy human body, where they form complex ecological communities and influence the  
23 human physiology (12). Even though the respiratory microbiota had not been so studied as that  
24 of other anatomical areas, such as the gut, due to the old paradigm that lungs were sterile (13, 14),  
25 recent studies have demonstrated that changes in the nasopharyngeal microbiota clearly correlate  
26 with increased or reduced susceptibility to different viral infections in humans (13). Indeed,  
27 focusing on COVID-19 research, dozens of studies have already tried to elucidate whether SARS-  
28 CoV-2 infection or the COVID-19 disease severity are associated with changes in the  
29 nasopharyngeal microbiota (14). However, unfortunately, the analysis of all these previous studies

1 reveals extremely variable and contradictory results, which prevent solid and reliable conclusions  
2 from being drawn (14).

3         Given that the aforementioned variability could be mostly avoided as its possible sources  
4 have already been identified and discussed in depth (14), and the importance that the  
5 characterization of the correlations between changes in the nasopharyngeal microbiota and the  
6 infection by SARS-CoV-2 or the COVID-19 disease severity could have from a biomedical point  
7 of view, further research that provides new knowledge to this field while avoiding that variability  
8 is essential. Thus, the new pieces that are added to the still lacunar knowledge on nasopharyngeal  
9 microbiota and COVID-19 could open new therapeutic avenues to reduce the severity of COVID-  
10 19 patients and/or improve their disease outcome, for example with the strategy of manipulating  
11 the nasopharyngeal microbiota, which has already worked in the treatment of other diseases such  
12 as metabolic disorders, cancer, and other viral infections (15-17).

13         Here, we elude the majority of the previously identified potential sources of variability (14)  
14 and extend the study where we already characterized in detail the nasopharyngeal microbiota of  
15 healthy people throughout life (18), to now analyse the changes in such microbiota in COVID-19  
16 patients with different disease severities and at all stages of life. For this, we analyse the diversity  
17 and relative abundance of the nasopharyngeal microbiota across the whole lifespan in a total of  
18 395 individuals of all ages, both sexes, and with different COVID-19 disease severities, and the  
19 taxonomic changes in the nasopharynx associated to these parameters. We therefore provide a very  
20 comprehensive and valuable dataset that will allow to identify the possible relationships between  
21 changes in nasopharyngeal microbiota and susceptibility to or severity of COVID-19, with special  
22 interest in the most susceptible groups such as the elderly (6).

23

## 24 **METHODS**

### 25 **Sample selection, collection, and classification**

26         The uninfected nasopharyngeal control samples were selected, collected, and classified as  
27 previously described (18). Besides those uninfected samples, and according to our experimental  
28 design and economic resources, we decided to select and collect a maximum of 360  
29 nasopharyngeal samples from SARS-CoV-2 infected individuals with different ages and COVID-

1 19 disease severity, as will be detailed here after (Table S1). These samples were randomly  
2 selected from a cohort of 4,996 SARS-CoV-2 infected subjects belonging to the Health Area I of  
3 the Region of Murcia (Spain) who voluntarily provided their samples between 1 September 2020  
4 and 3 November 2020 for diagnostic purposes and tested positive for SARS-CoV-2 infection.  
5 Nasopharyngeal swabs were obtained by approaching the nasopharynx transnasally and stored in  
6 Universal Transport Medium (UTM): Viral Transport medium (COPAN Diagnostics Inc.,  
7 Murrieta, CA, USA). Nucleic acid extraction was performed using the automatized system  
8 Nuclisens Easymag (bioMérieux, Madrid, Spain) based on the ability of silica to bind DNA and  
9 RNA in high salt concentrations (Boom technology). The polymerase chain reaction (PCR) kit  
10 used to verify that all the samples were positive for SARS-CoV-2 infection was Novel Coronavirus  
11 (2019-nCoV) Real Time Multiplex RT-PCR kit (Detection for 3 Genes), manufactured by  
12 Shanghai ZJ Bio-Tech Co., Ltd. (Liferiver Biotech, la Jolla, CA, USA) and the CFX96 Touch  
13 Real-Time PCR Detection System (BioRad, Madrid, Spain).

14 To facilitate the study of sex-, age, and COVID-19 disease severity-associated changes in  
15 the nasopharyngeal microbiota, and to ensure that the sample size of all the sex, age, and disease  
16 severity groups were homogeneous, we decided on an experimental design that distributed the  
17 maximum of 360 infected nasopharyngeal samples that we could analyse into three COVID-19  
18 disease severity groups (mild, moderate, and severe) with a maximum of 120 individuals each,  
19 each divided into six age groups with 20 individuals each, of which 10 were females and the other  
20 10 were males (Table S1). For this, the 4,996 SARS-CoV-2 infected individuals of our parent  
21 cohort were first divided into their COVID-19 disease severity matched groups, and later into their  
22 age matched groups within each of the severity groups and numbered. Then, randomly obtained  
23 numbers were used to select 10 females and 10 males from each of the age groups within each of  
24 the severity groups. Random numbers were generated in RANDOM.ORG, which is a True  
25 Random Number Generator (TRNG) that generates true randomness via atmospheric noise, unlike  
26 the most common and less trustworthy Pseudo-Random Number Generators (PRNGs)  
27 [RANDOM.ORG: True Random Number Service. Available at: <https://www.random.org>]. The  
28 reason that some groups contained fewer patients than planned in our experimental design, or even  
29 none such as patients under 20 years of age with moderate or severe COVID-19 disease severity,  
30 is that patients with these characteristics are rare and we simply enrolled all patients with such  
31 characteristics who were in our parent cohort (Table S1). Our COVID-19 disease severity groups

1 were established according to the World Health Organization (WHO) COVID-19 severity  
2 classification [[https://iris.who.int/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-  
3 2020.5-eng.pdf](https://iris.who.int/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf)], with the only difference that the ‘severe disease’ and ‘critical disease’ groups  
4 established by the WHO are both gathered in our group of severe COVID-19. Finally, while the  
5 exclusion criteria for the uninfected nasopharyngeal samples were already described (18), the only  
6 SARS-CoV-2 infected individuals excluded from this study were those younger than 1 year as the  
7 microbiome of infants is known to be highly fluctuating with age and, therefore, it could  
8 significantly increase the variability of our analyses.

9

## 10 **Amplification, library preparation, and sequencing**

11 Exactly as previously described for our uninfected control cohort (18).

12

## 13 **Bioinformatics and statistical analysis**

14 The obtained sequences were analysed and annotated with the Ion Reporter 5.18.2.0  
15 software (Thermo Fisher Scientific Inc., Alcobendas, Spain) using the 16S rRNA Profiling  
16 workflow 5.18. Clustering into OTUs and taxonomic assignment were performed based on the  
17 Basic Local Alignment Search Tool (BLAST) using two reference libraries, MicroSEQ® 16S  
18 Reference Library v2013.1 and the Greengenes v13.5 database. For an OTU to be accepted as  
19 valid, at least ten reads with an alignment coverage  $\geq 90\%$  between hit and query were required.  
20 Identifications were accepted at the genus and species level with sequence identity  $> 97\%$  and  $>$   
21  $99\%$ , respectively. Annotated OTUs were then exported for analysis with R (v.4.1.2)  
22 (<https://www.R-project.org/>), where data were converted to phyloseq object (19) and abundance  
23 bar plots and heatmaps were generated. Data were converted to DESeq2 object (20), that uses a  
24 generalized linear model based on a negative binomial distribution, to calculate differential  
25 abundance between groups. Thus, the differential abundance analysis was conducted according to  
26 the phyloseq package vignette with bioconductor DESeq2  
27 ([https://bioconductor.org/packages/devel/bioc/vignettes/phyloseq/inst/doc/phyloseq-mixture-  
28 models.html#import-data-with-phyloseq-convert-to-deseq2](https://bioconductor.org/packages/devel/bioc/vignettes/phyloseq/inst/doc/phyloseq-mixture-models.html#import-data-with-phyloseq-convert-to-deseq2), accessed on 16 November 2023). The  
29 raw abundance matrix was imported into phyloseq object (as specified in the documentation of

1 phyloseq with DESeq2) and subsequently converted to DESeq2 object. Then, estimated size  
2 factors were used with the DESeq2 function to obtain the differential abundance. DESeq  
3 automatically searches for outliers and, if possible, replaces the outlier values estimating mean-  
4 dispersion relationship. If it's not possible to replace, then p-values are replaced by NA. R (v.4.1.2)  
5 was also used to perform a principal coordinates analysis (PCoA) on Bray-Curtis dissimilarity  
6 measures among samples based on relative OTU abundances (i.e., percentages). The relative  
7 abundances of OTUs were also used to test for statistically significant differences between age  
8 groups. Group OTU compositions were compared through the non-parametric statistical tool  
9 ANOSIM. The 90% confidence data ellipses for each of the age groups were plotted. Alpha  
10 diversity was estimated based on Shannon and Inverse Simpson indices by using the phyloseq  
11 package. To test for statistically significant differences between age or COVID-19 disease severity  
12 groups in alpha diversity, the non-parametric Wilcoxon test was used. Heatmaps were generated  
13 by calculating the average abundance of each age group for each severity level. The values shown  
14 in the heatmaps were logarithmically transformed. The 'heatmap.2' function from the 'gplots'  
15 package in R was used for the visualization (<https://CRAN.R-project.org/package=gplots>,  
16 accessed on 16 November 2023). The bar plots aggregated by age groups show the aggregated  
17 relative abundance (sum of relative abundances). Krona charts, that aid in the estimation of relative  
18 abundances even within complex metagenomic classifications, were generated as previously  
19 described (21). All the other graphs were generated with the R package ggplot2 version 3.3.3.,  
20 including the confidence data ellipses which were plotted using the 'stat\_ellipse' function also  
21 from this package (22).

22

## 23 **RESULTS**

### 24 **Data annotation**

25 A total of 395 nasopharyngeal microbiomes from 117 uninfected control subjects and 278  
26 SARS-CoV-2 infected individuals were analysed (Table S1). A total of 30,535,433 high quality  
27 16S rRNA sequences ranging from 8,969 to 330,138 sequences per sample (mean = 77,305;  
28 median = 64,368) were obtained after quality control analyses and OTU filtering. The 16S rRNA  
29 sequences were binned into 167 families, 329 genera and 671 species. Considering all the samples  
30 together, the most abundant families were Moraxellaceae (26.4%), Pseudomonadaceae (15.8%),

1 Prevotellaceae (12.0%), Streptococcaceae (11.0%) and Enterobacteriaceae (10.8%). The most  
2 abundant genera were *Acinetobacter* (28.2%), *Pseudomonas* (18.8%), *Streptococcus* (12.8%),  
3 *Prevotella* (11.9%) and *Brevundimonas* (6.5%). The most abundant species were *Acinetobacter*  
4 *johnsonii* (22.6%), *Prevotella melaninogenica* (19.0%), *Dolosigranulum pigrum* (13.4%),  
5 *Ralstonia pickettii* (9.0%) and *Brevundimonas halotolerans* (8.7%). To reveal any potential  
6 changes in the nasopharyngeal microbiota associated to COVID-19 disease severity, we split the  
7 samples into 4 disease severity groups, namely, (1) uninfected control subjects (N = 117); (2)  
8 COVID-19 patients with mild symptoms (N = 116); (3) COVID-19 patients with moderate  
9 symptoms (N = 97); and (4) COVID-19 patients with severe symptoms (N = 65) (Table S1).  
10 Moreover, each of these disease severity groups were divided into 6 age groups covering all stages  
11 of life, each divided into females and males to be able to also study possible age- and sex-  
12 associated differences (Table S1). Whenever possible, there were 20 samples in each age group  
13 and 10 samples in each sex group within them (Table S1). Of the total of 30,535,433 high quality  
14 16S rRNA sequences, 4,427,438 sequences corresponded to the uninfected control subjects  
15 (ranging from 10,627 to 256,449 sequences per sample; mean = 37,841; median = 33,134),  
16 7,327,367 sequences corresponded to the COVID-19 patients with mild symptoms (ranging from  
17 8,969 to 223,499; mean = 63,167; median = 53,964), 9,412,508 sequences corresponded to the  
18 COVID-19 patients with moderate symptoms (ranging from 43,029 to 299,919; mean = 97,036;  
19 median = 82,570), and 9,368,120 sequences corresponded to the COVID-19 patients with severe  
20 symptoms (ranging from 71,150 to 330,138; mean = 144,125; median = 137,086). All the  
21 previously mentioned 167 families, 329 genera and 671 species were identified in the 4 different  
22 disease severity groups established for this study. A simple first analysis of the most abundant taxa  
23 at the family, genus, and species levels in each of the COVID-19 disease severity groups (Fig. 1a-  
24 c), but focusing mainly on the genus level which is the one that can give us more relevant  
25 information (as the family level is too general, whereas the taxonomic assignment at the species  
26 level may not be fully accurate with the 16S rRNA gene sequencing approach used in this study),  
27 revealed some interesting differences (Fig. 1b). Notably, *Dolosigranulum* and *Ralstonia* were  
28 among the ten most abundant bacterial genera in uninfected control subjects but were not found in  
29 COVID-19 patients with any severity, *Veillonella* was absent only in uninfected controls, and  
30 *Rothia* was among the ten most abundant genera only in severe COVID-19 patients while absent



1 in the rest of the severity groups (Fig. 1b). Furthermore, *Acinetobacter* relative abundance was  
2 clearly higher in COVID-19 patients compared to uninfected controls (Fig. 1b).

3

#### 4 **Clustering patterns of nasopharyngeal samples**

5 With the aim of analyzing how different samples were grouped according to their OTU  
6 composition, we applied principal coordinates analysis (PCoA), which is a powerful statistical tool  
7 that enables complex multivariate data sets to be visualized in a reduced number of dimensions  
8 (23). This allowed us to determine the clustering patterns of samples according to their Bray-Curtis  
9 distances, which were calculated based on the relative abundance matrices of the genera across the  
10 samples pertinent in each case (Fig. 2). The analysis of similarities (ANOSIM), which is a  
11 nonparametric statistical test, was then used to analyse whether there were statistically significant  
12 differences among the different age and severity groups included in this study (Fig. 2 and Table  
13 S2). The comparison between the different age groups without any stratification by COVID-19  
14 severity showed that, although samples appeared to be mostly intermixed and the different  
15 confidence ellipses overlapped each other, there were significant differences in 7 out of the 15  
16 possible comparisons, highlighting the fact that the group containing people over 70 years of age  
17 was significantly different to 4 of the other 5 age groups (Fig. 2a and Table S2). Interestingly, the  
18 comparison between the COVID-19 disease severity groups without any prior stratification by age  
19 revealed that all groups were significantly different from each other (Fig. 2b and Table S2). Then,  
20 to study all these differences in more depth, we first stratified the samples by severity and  
21 subsequently compared between the different age groups within each severity group (Fig. 2c). A  
22 previous work already compared the age groups and analysed the clustering patterns of our control  
23 samples according to their Bray-Curtis distances, finding significant differences only between the  
24 age groups A1-A4 and A1-A5 (18). When we did the same analysis for the other COVID-19  
25 severity groups, some of the possible comparisons resulted in significant differences in mild and  
26 moderate COVID-19 patients (6 out of 15 and 6 out of 10, respectively) (Fig. 2c and Table S2).  
27 However, curiously, only there were significant differences between the age groups A3 and A4 in  
28 severe COVID-19 patients (Fig. 2c and Table S2). Finally, the samples were stratified first by age  
29 and later the COVID-19 severity groups were compared within each age group, finding that,

1 surprisingly, the majority of the possible comparisons were significantly different (24 out of 31)  
2 (Fig. 2d and Table S2).

3

#### 4 **Nasopharyngeal bacterial diversity decreases progressively throughout life in severely ill** 5 **COVID-19 patients**

6 The fact that previous data on bacterial diversity in the nasopharynx of COVID-19 patients  
7 were highly variable and contradictory (14), prompted us to check it as our experimental design  
8 avoids many of the limitations that are likely the sources of that variability (14) and, therefore, we  
9 could shed light on this issue. Hence, we analysed the alpha diversity, referred to as within-  
10 community diversity (24), in the nasopharynx of the different age and severity groups established  
11 for this study (Table S1). The Shannon's diversity index, which measures evenness and richness  
12 of communities within a sample, did not show significant changes in bacterial diversity among the  
13 different age (Fig. 3a) or severity (Fig. 3b) groups when all the individuals enrolled in this study  
14 were included in the analyses without any previous stratification. The only exception was the  
15 comparison between COVID-19 patients with mild symptoms and those with moderate ones, since  
16 bacterial diversity was significantly lower in the second group (Fig. 3b). Interestingly, when we  
17 compared the age groups after having first stratified the individuals by their COVID-19 severity,  
18 we found that bacterial diversity progressively decreased throughout life in patients with severe  
19 COVID-19, whereas no significant changes between any age groups appeared in COVID-19  
20 patients with mild or moderate symptoms (Fig. 3c). In addition, we have previously demonstrated  
21 the absence of any significant changes in alpha diversity in the uninfected control cohort (18).  
22 Finally, the comparison between the different COVID-19 severity groups after having first  
23 separated the individuals by age, revealed significant changes only between mild and moderate as  
24 well as between moderate and severe COVID-19 patients who are in their 20s and 30s (Fig. 3d).  
25 To confirm our results, we utilized another index commonly used to measure alpha diversity such  
26 as the inverse Simpson's diversity index, which is an indication of the richness in a community  
27 with uniform evenness that would have the same level of diversity. Importantly, results were  
28 almost identical to the observed with the Shannon's diversity index (Fig. S1a-c), including the  
29 clear and progressive reduction in bacterial diversity in the nasopharynx of severely ill patients as  
30 they age (Fig. S1c).

## 1 Age- and severity-associated changes in relative abundance of bacterial taxa in the 2 nasopharynx of COVID-19 patients

3 We sought to determine the differences in nasopharyngeal taxa abundance among age and  
4 severity classes, so we compared the nasopharyngeal microbiota of COVID-19 patients of the  
5 different age groups within each of the four disease severity groups established for this study (Fig.  
6 4a), and vice versa (Fig. 4b and Table S1). We considered that focusing our analyses at the genus  
7 level would be the most informative since, as previously mentioned, the phylum or family levels  
8 are too general, whereas the taxonomic assignment at the species level may not be fully accurate  
9 with our 16S rRNA gene sequencing approach. To facilitate the interpretation of a so complex  
10 analysis, we selected only the 57 bacterial genera whose relative abundance was higher than 1%  
11 in at least one of the age groups and decided to perform heatmap plots to jointly and visually show  
12 the results of all the possible comparisons between age groups within each severity group (Fig.  
13 4a), as well as between severity groups within each age group (Fig. 4b). Note that, in some cases,  
14 the differences described below were easier to appreciate when the abundance data were  
15 represented on a linear scale (Fig. S2), rather than on the more commonly used logarithmic scale  
16 that allows to visualize differences when abundance is low (Fig. 4). The comparison between age  
17 groups within each of the COVID-19 severity groups showed that, overall, the most abundant  
18 bacterial genera shared among all severity groups were *Staphylococcus*, *Dolosigranulum*,  
19 *Corynebacterium*, *Streptococcus*, *Moraxella*, *Prevotella*, *Acinetobacter*, *Pseudomonas*, and  
20 *Brevundimonas* (Fig. 4a and S2a). However, in the cases of *Streptococcus*, *Prevotella*,  
21 *Acinetobacter*, *Pseudomonas*, and *Brevundimonas*, their relative abundances were higher in  
22 COVID-19 patients of any severity than in uninfected control individuals (Fig. 4a and S2a).  
23 Interestingly, *Sporobacterium*, *Turicella*, and *Cetobacterium* were detected only in uninfected  
24 controls of the different age groups whilst they were totally absent in COVID-19 patients  
25 independently on their disease severity (Fig. 4a). The cases of *Acinetobacter*, *Pseudomonas*, and  
26 *Brevundimonas* were curious as their abundances increased progressively with age in the majority  
27 of the severity groups (Fig. 4a and S2a). Notably, the bacterial genera *Spirochaeta* and *Scardovia*  
28 were present only in severe COVID-19 patients, being even more interesting the case of *Scardovia*  
29 since it was detected exclusively in individuals over 60 years of age (Fig. 4a). As these results  
30 suggested a potential utility of *Spirochaeta* and *Scardovia* as biomarkers of COVID-19 disease  
31 severity in aged patients, which are the most susceptible to the disease (25), we tried to identify

1 which species of these genera were present in our samples. Thus, while the 16S rRNA gene  
2 sequencing approach used in this study did not allow us to identify any *Spirochaeta* species (Fig.  
3 5a), fortunately we were able to determine that the species of *Scardovia* present in our samples  
4 was *Scardovia wiggsiae* in more than 99% of the cases (Fig. 5b). Besides confirming all the  
5 aforementioned changes in relative abundance, as was logical and expected, the new perspective  
6 we had by plotting our relative abundance results as the comparison between the different COVID-  
7 19 disease severity groups within each of the age groups, allowed us to observe a higher relative  
8 abundance of *Staphylococcus*, *Corynebacterium*, *Streptococcus*, *Prevotella*, *Acinetobacter*, and  
9 *Pseudomonas* as the COVID-19 severity increased within most of the age groups (Fig. 4b and  
10 S2b).

11 Finally, aiming to identify any statistically significant age-associated changes in the  
12 nasopharyngeal microbiota of COVID-19 patients, we focused on the bacterial genera whose  
13 relative abundances were significantly different between the distinct age groups within each of the  
14 severity groups (Fig. 6). We had already been reported in a previous study with the uninfected  
15 control cohort that there were statistically significant differences in relative abundance between  
16 the distinct age groups in the 11 bacterial genera *Acinetobacter*, *Brevundimonas*, *Dolosigranulum*,  
17 *Finegoldia*, *Haemophilus*, *Leptotrichia*, *Moraxella*, *Peptoniphilus*, *Pseudomonas*, *Rothia*, and  
18 *Staphylococcus* (18). Curiously, our results showed that the number of bacterial genera which  
19 presented statistically significant differences in relative abundance between the age groups clearly  
20 decreased as the COVID-19 disease severity increased, with 23 genera presenting such differences  
21 in COVID-19 patients with mild symptoms (Fig. 6a and Table S3), 15 genera in patients with  
22 moderate symptoms (Fig. 6b and Table S3), and only 4 genera in individuals suffering from severe  
23 COVID-19 (Fig. 6c and Table S3). Differences between age groups were statistically significant  
24 in 74 cases in the 23 bacterial genera that presented this type of differences in mild COVID-19  
25 patients, in 52 cases in the 15 genera that presented them in moderate COVID-19 patients, and in  
26 13 cases in the 4 genera that presented them in severely ill COVID-19 patients (Table S3).  
27 Curiously, the age group A6 was the one that presented statistically significant differences with  
28 respect to other age groups in more cases in mild and moderate COVID-19 patients, but not in  
29 patients with severe symptoms (Table S3).

30

## 1 **DISCUSSION**

2           After characterizing the healthy human nasopharyngeal microbiota (18), we sought to  
3 study any possible links between alterations of this microbiota and SARS-CoV-2 infection, with  
4 special attention to the COVID-19 clinical outcome, as this is a crucial question from a biomedical  
5 and clinical point of view that remains unresolved. But the problem is not the lack of studies on  
6 this, since dozens of works have already addressed this topic, but rather that their results are  
7 extremely variable and contradictory (14). In a recent previous work, we identified and discussed  
8 in depth the potential sources of such high variability study by study, highlighting the low sample  
9 sizes, the heterogeneity of the enrolled subjects, the different sequencing technologies used, or the  
10 lack of standardization of the criteria utilized to stratify individuals, among others (14). Thus, in  
11 the present study we have tried to avoid the mentioned sources of variability, as far as possible,  
12 aiming to obtain soundness data on any significant sex-, age-, or disease severity-associated  
13 changes in the nasopharyngeal microbiota of COVID-19 patients. Regarding sex-associated  
14 changes, no significant differences in any of the parameters analysed in this study were found at  
15 all, including within any of the age or COVID-19 disease severity groups investigated. This is  
16 consistent with the findings of a previous study using our uninfected control cohort to characterize  
17 the nasopharyngeal microbiota of healthy subjects, that revealed the absence of any relevant  
18 differences between males and females (18), and confirms that nasopharyngeal microbiota does  
19 not behave as that of other anatomical areas such as the gut, where there are significant sex-  
20 associated differences in diversity and taxonomic composition, probably due to the distinct levels  
21 of sex hormones (12, 26, 27). Therefore, analyses by sex are not showed in this work given their  
22 total irrelevance and to simplify the analysis and interpretation of the age- and disease severity-  
23 associated differences.

24           Our initial PCoA analyses to determine the clustering patterns of the nasopharyngeal  
25 samples revealed that, without any prior stratification by COVID-19 disease severity, the age  
26 group containing people over 70 years of age was the most different from the rest of age groups.  
27 This was the first hint that the results of the oldest people were going to be some of the most  
28 interesting findings throughout this study, as will be seen below. After this promising beginning,  
29 we decided to analyse alpha diversity. It had previously been observed that alpha diversity, which  
30 summarizes the distribution of species abundances in a given sample into a single number that

1 depends on species richness and evenness, and is a central topic in microbiome data analysis (24),  
2 was not significantly different in any case when comparing between age groups in the uninfected  
3 cohort used as a control in this study (18). Similarly, analysing bacterial species richness in the  
4 nasopharynx of subjects of the different age and COVID-19 disease severity groups established  
5 for this study, revealed no age- or severity-associated relevant differences in alpha diversity, with  
6 the only striking exception of COVID-19 patients with severe symptoms, whose alpha diversity  
7 decreased progressively as their age increased. This was confirmed by using two of the most  
8 reliable and commonly used alpha diversity indexes, such as the Shannon's diversity index and  
9 the inverse Simpson's diversity index, which resulted in almost identical results. The general lack  
10 of differences in alpha diversity found in this work is consistent with the results of many previous  
11 studies that observed the same when comparing the nasopharyngeal microbiota of COVID-19  
12 patients with that of uninfected controls (28-34), whereas, in accordance with the variability  
13 prevailing in this field until now, other studies had reported that alpha diversity decreased in  
14 COVID-19 patients compared to uninfected controls (35, 36), that it decreased in the most severe  
15 cases of COVID-19 compared to milder cases (37-40), and even that it increased in SARS-CoV-2  
16 infected pregnant women compared to uninfected (41). Unfortunately, the already mentioned  
17 limitations present in all these previous studies (14), together with the fact that their experimental  
18 designs did not allow the analysis of the nasopharyngeal microbiota of COVID-19 patients with  
19 different disease severities at all stages of their lives, prevented them from finding the progressive  
20 alpha diversity reduction in severe COVID-19 patients uncovered in this work. Curiously, similar  
21 reductions in alpha diversity with aging had been observed before in the gut of healthy subjects  
22 (42), but in that case the differences are probably due to aging-associated factors that affect the gut  
23 microbiota in a more intense way compared to the nasopharyngeal microbiota, such as the increase  
24 of coliform numbers and changes in diet (43). In summary, our analyses have revealed for the first  
25 time, to our knowledge, that alpha diversity progressively decreases with aging but only in patients  
26 with severe COVID-19, strongly suggesting an association between this reduced bacterial diversity  
27 and the fact that aged individuals are more susceptible to COVID-19 and present more severe  
28 forms of the disease (6).

29 The use of heatmaps, that represent the magnitude of individual values within a dataset as  
30 a colour, allowed us to analyse our complex taxa abundance results at the genus level in a simpler  
31 and more visual manner. Cases in which a bacterial genus is present or absent exclusively in a

1 certain COVID-19 disease severity group are particularly relevant from a biomedical point of  
2 view, since the presence/absence of such microorganism could potentially serve as a biomarker of  
3 disease severity. This is exactly what we observed for the bacterial genera *Sporobacterium*,  
4 *Turicella* and *Cetobacterium*, which were abundant in uninfected individuals while totally absent  
5 in COVID-19 patients independently on their disease severity. Even more striking was the finding  
6 that *Spirochaeta* and *Scardovia* were present only in COVID-19 patients with severe symptoms,  
7 being particularly relevant the case of *Scardovia* as it appeared exclusively in subjects over 60  
8 years of age. The 16S rRNA gene sequencing approach used in this study, which is by far the most  
9 common technique to study microbiota in clinical samples, has the limitation that its taxonomic  
10 resolution often does not allow identification beyond the genus level (44), as we found in the case  
11 of *Spirochaeta*. However, fortunately, our analyses were able to determine that the bacteria of the  
12 genus *Scardovia* identified in severe COVID-19 patients over 60 years of age were of the species  
13 *S. wiggsiae* in more than 99% of the cases. *S. wiggsiae*, a gram-positive, anaerobic, nonspore  
14 forming, and nonmotile bacilli removed from the genus *Bifidobacterium* in 2002 due to difference  
15 in its genome sequence (45), was classified as part of the human oral microbiome (46) and later  
16 identified as a predominant caries pathogen, even in the absence of *Streptococcus mutans* (47, 48).  
17 Furthermore, our novel finding that *Scardovia* was present only in the nasopharynx of severe  
18 COVID-19 patients over 60 years of age was consistent with a previous study that analysed the  
19 nasal/oropharyngeal microbiota of COVID-19 patients with different disease severities, where  
20 *Scardovia* was detected only in intensive care unit patients, albeit unfortunately those patients were  
21 not stratified by age (49). Therefore, all these data together suggest that while bacteria from the  
22 genus *Scardovia* are present in the oral microbiota (46), they are also capable of colonizing other  
23 close ecological niches such as the nose, oropharynx, and nasopharynx in severely ill COVID-19  
24 patients (49). Although it seems counterintuitive, it is well known that nearby anatomical areas  
25 closely related in terms of structure and function can present different microbiotas and even niche-  
26 specific bacteria, as previously demonstrated, for example, for the cases of nasopharynx and nose  
27 that are adjacent (50). In the present case, thinking of the possible changes in the nasopharynx of  
28 severely ill COVID-19 patients that allow *Scardovia* to colonize new anatomical areas of their  
29 upper respiratory tract, such alterations may be caused by the replication of the SARS-CoV-2 virus  
30 itself or by the inflammatory processes in response to the infection that disrupt the physical-  
31 chemical barriers. Undoubtedly, this issue will deserve further research. Note that even though the

1 intubation procedures can also alter the nasopharynx in severe patients, this is not applicable to the  
2 present study as our samples were collected in early stages of the disease. In addition, it was  
3 particularly concerning, from a clinical perspective, that the opportunistic pathogen bacterial  
4 genera *Staphylococcus*, *Corynebacterium*, *Streptococcus*, *Prevotella*, *Acinetobacter*, and  
5 *Pseudomonas* were overrepresented in the nasopharynx of severely ill COVID-19 patients. An  
6 important question here is whether the previously mentioned changes in the nasopharynx as  
7 consequence of a severe COVID-19 disease allow a greater proliferation of these opportunistic  
8 microorganisms in the nasopharynx, or whether, on the contrary, a greater previous abundance of  
9 these bacterial genera in the nasopharynx predisposes subjects to suffer more serious forms of the  
10 COVID-19 disease. Since, as already mentioned, our samples were collected in early stages of the  
11 disease, the second hypothesis is probably the correct one.

12 Our taxa abundance analyses at the genus level detected statistically significant relative  
13 abundance differences between the distinct age groups for 23 bacterial genera in COVID-19  
14 patients with mild symptoms, for 15 genera in patients with moderate disease severity, and only  
15 for 4 genera in severely ill patients. The reason why the number of bacterial genera presenting  
16 significant differences between age groups decreased as the COVID-19 disease severity increased  
17 is enigmatic, but we can hypothesize that the previously mentioned changes induced by the  
18 COVID-19 disease alter the conditions of the nasopharynx as an ecological niche to such an extent  
19 at any age, that it determines which bacterial genera can live there independently of the age of the  
20 patients. In other words, the significant relative abundance differences between age groups  
21 observed in COVID-19 patients with mild or moderate severities, could be counteracted in severe  
22 patients by a more powerful factor such as the alterations in the nasopharynx caused by the  
23 COVID-19 disease, proportionally to its severity. This hypothesis is supported by the fact that  
24 52.7% (39 out of 74) of the relative abundance statistically significant differences in mild COVID-  
25 19 patients, 67.3% (35 out of 52) in moderate patients, whereas only 23.1% (3 out of 13) in severe  
26 patients, were between the age group A6 and other age groups. Thus, while A6 clearly is the most  
27 different group from the other age groups in mild and moderate COVID-19 patients, this dynamic  
28 is broken in severe patients where probably the alterations as consequence of the disease are the  
29 predominant factor.



1           As previously mentioned, this study was designed trying to avoid, as much as possible, the  
2 limitations that we identified in a recent work (14) as the greatest sources of data variability on  
3 this field. Good examples of this are our high sample size, our stratification of subjects by age in  
4 groups that cover the entire life, or how our samples were collected from a very short period of  
5 time that comprised a single SARS-CoV-2 infection wave at an early point in the pandemic, thus  
6 avoiding the risk of recruiting patients infected by different SARS-CoV-2 variants that are already  
7 known to elicit different immune responses that could alter the nasopharyngeal microbiota  
8 differentially (51). Nevertheless, our study still has several limitations. This was an observational,  
9 retrospective study, and collection of data was not standardized in advance. Even though it is the  
10 most common technique to study microbiota in clinical samples, the 16S rRNA gene sequencing  
11 approach to study the microbiota could introduce bias in the obtained data because this method  
12 does not allow the study of the whole microbiome, but only the genera amplified by PCR.  
13 Moreover, it was not possible to obtain serial samples. Furthermore, the sex groups within each  
14 age group are small, so the study may have been underpowered to detect certain associations.  
15 Finally, we could not access any sociodemographic, environmental, lifestyle, or medical  
16 information of subjects enrolled in this study, which would have been helpful to better understand  
17 the characteristics of the cohort.

18           Notably, some of the most clear and interesting differences found in this study were those  
19 that affected the elderly, who are the most susceptible to developing serious forms of the COVID-  
20 19 disease (25). Thus, they were (1) the more different age group compared to the other age groups,  
21 without any prior stratification by COVID-19 disease severity, according to our PCoA analyses;  
22 (2) the age group that presented a greater reduction in alpha diversity in severely ill COVID-19  
23 patients; (3) the age group involved in more comparisons between age groups that resulted in  
24 statistically significant differences, and (4) only severe COVID-19 patients over 60 years of age  
25 presented the bacteria *S. wiggisiae* -potentially useful as a severity biomarker in these individuals-  
26 in their nasopharynx. In addition, the relative abundances of opportunistic bacterial pathogens such  
27 as *Moraxella* and *Acinetobacter* were increased in aged severe COVID-19 patients compared with  
28 younger patients with the same disease severity. Therefore, we can hypothesize that there may be  
29 some correlation between the increased susceptibility of aged subjects to COVID-19 (25), and  
30 their nasopharyngeal taxonomic composition. Hence, future metagenomic studies collecting  
31 samples at different time points will be paramount to elucidate when the mentioned changes in the

1 nasopharyngeal microbiota of aged individuals occur, aiming to determine whether such changes  
2 are cause or consequence of the COVID-19 disease and, therefore, if they could be useful as  
3 prognosis or severity biomarkers in the elderly. Moreover, this could also be useful to stratify  
4 COVID-19 aged patients, and paves the way for new therapeutic avenues such as nasopharyngeal  
5 microbiota manipulation, which is an approach that has already been successfully exploited in  
6 different medical fields, from cancer to metabolic disorders and viral infection (15-17, 52).

7

## 8 **Acknowledgements**

9 We thank the staff of the Genomics facility of IMIB Pascual Parrilla for 16S rRNA sequencing,  
10 and the staff of the Microbiology Service at HCUVA for sample collection and processing.

## 11 **Author contributions**

12 The authors offer the following declarations about their contributions: Conceived and designed the  
13 experiments: VM, MLC and SC. Performed the experiments: FPS, SDT, CAS and SC. Analysed  
14 the data: FPS, SDT, CAS, VM, MLC and SC. Provided patients' samples: AMD. Writing-original  
15 draft: SC. Writing-review & editing: VM and MLC. All authors have read and agreed to the  
16 published version of the manuscript.

## 17 **Funding**

18 This work was supported by the grant 00006/COVI/20 to VM and MLC funded by Fundación  
19 Séneca-Murcia, the Saavedra Fajardo contract 21118/SF/19 to SC funded by Fundación Séneca-  
20 Murcia, the Juan de la Cierva-Incorporación contract to SDT funded by Ministerio de Ciencia y  
21 Tecnología/AEI/FEDER. The funders had no role in the study design, data collection and analysis,  
22 decision to publish, or preparation of the manuscript.

## 23 **Availability of data and materials**

24 Raw sequencing data of all 16S rRNA sequences and metadata are available at the open access  
25 repository Figshare under the accession numbers 10.6084/m9.figshare.24504259 and  
26 10.6084/m9.figshare.24504262, respectively.

## 27 **Institutional review board statement**

1 All procedures in this work were carried out following the principles expressed in the Declaration  
2 of Helsinki, as well as in all the other applicable international, national, and/or institutional  
3 guidelines for the use of samples and data, and have been approved by the Comité de Ética de la  
4 Investigación (CEIm) at Hospital Clínico Universitario Virgen de la Arrixaca (protocol number  
5 2020-10-12-HCUVA—Effects of aging in the susceptibility to SARS-CoV-2).

#### 6 **Informed consent statement**

7 Nasopharyngeal swabs were collected for diagnosis of SARS-CoV-2 infection before this study  
8 was conceived, without the need of any informed consent as the collection procedure was non-  
9 invasive and risk-free. However, when the COVID-19 pandemic spread out of control, samples  
10 were kept at the Microbiology Service instead of destroyed after diagnosis as it was considered  
11 that they might be extremely relevant for research. This, together with the facts that (i) the  
12 retrospective use of these samples did not affect donor health or treatment at all, (ii) all data has  
13 been treated anonymously, and (iii) movement was limited due to the exceptional circumstances  
14 of the pandemic meant that it was not possible to obtain informed consents for the use of these  
15 samples in research. Moreover, none of the subjects expressly objected to their samples being used  
16 for research.

#### 17 **Competing interests**

18 The authors declare no competing interests.

19

20

## 1 **Figure legends**

2 **Figure 1. Most abundant taxa in each of the COVID-19 disease severity groups established**  
3 **for this study.** Among the 167 families, 329 genera, and 671 species that were identified, all of  
4 them present in each of the 4 severity groups, the 10 more abundant taxa at the family (**a**), genus  
5 (**b**) and species (**c**) levels in each of the COVID-19 severity groups are shown.

6

7 **Figure 2. Microbial community composition.** Principal coordinates analysis (PCoA) plots of the  
8 Bray-Curtis distances which were calculated based on the relative abundance matrices of the  
9 genera across the samples pertinent in each case, for the age groups without any prior stratification  
10 by COVID-19 disease severity (**a**), for the disease severity groups without any prior stratification  
11 by age (**b**), for the age groups within each of the disease severity groups (**c**), and for the disease  
12 severity groups within each of the age groups (**d**). In all cases, the data were linearly transformed  
13 and visualized in two-dimensional space. Each sample is represented by one dot, colored according  
14 to age (**a, c**) or severity (**b, d**). The percentage of the variance of the original data explained by  
15 each of the two principal components is indicated in the axis labels. The 90% confidence data  
16 ellipses are shown for each age (**a, c**) or severity (**b, d**) group.

17

18 **Figure 3. Comparison of alpha diversity parameters across the age and COVID-19 disease**  
19 **severity groups studied.** Box-whisker plots showing the alpha diversity Shannon index values for  
20 the age groups without any prior stratification by COVID-19 disease severity (**a**), for the disease  
21 severity groups without any prior stratification by age (**b**), for the age groups within each of the  
22 disease severity groups (**c**), and for the disease severity groups within each of the age groups (**d**).  
23 Each sample is represented by one dot. The Wilcoxon signed-rank test was used to determine  
24 statistical significance ( $p\text{-value} < 0.05$ ) in the comparisons between the different groups, and, for  
25 clarity, only the statistically significant differences and their  $p$ -values are showed in the graphs (**a-**  
26 **d**). The age group A1 includes subjects between 1 and 20 years old, A2 between 21 and 40, A3  
27 between 41 and 50, A4 between 51 and 60, A5 between 61 and 70, and A6 includes individuals  
28 over 70 years of age (Table S1).

29

1 **Figure 4. Relative abundance of bacterial genera in the different age and COVID-19 severity**  
2 **groups.** Heatmaps showing the abundance for each of the age and severity groups established for  
3 this study of the 57 bacterial genera whose relative abundance is above 1% in at least one of the  
4 age groups. Data are showed in two different ways to facilitate the visualization and interpretation  
5 of such a complex data set: divided first by severity group and then by age group within each  
6 severity group (a), and divided first by age group and then by severity group within each age group  
7 (b). Data are shown on a logarithmic scale to facilitate the visualization of differences when  
8 abundance is low. Bacterial genera are arranged in decreasing order of abundance considering the  
9 first column on the left, which corresponds to the uninfected control subjects of the age group A1.

10

11 **Figure 5. Bacterial community composition of the family Spirochaetaceae and the genus**  
12 **Scardovia in severely ill COVID-19 patients over 70 years of age. a** Krona chart of the bacterial  
13 community composition of the family Spirochaetaceae in severe COVID-19 patients over 70 years  
14 of age, showing that our 16S rRNA gene sequencing approach was not able to go beyond the genus  
15 level in the case of the bacterial genus *Spirochaeta*. **b** Krona chart of the bacterial community  
16 composition of the genus *Scardovia* in severe COVID-19 patients over 70 years of age, showing  
17 that the bacteria from this genus was *Scardovia wiggisiae* in more than 99% of cases.

18

19 **Figure 6. Taxonomic composition of the bacterial genera which show significant differences**  
20 **between age groups in mild, moderate, and severe COVID-19 patients.** Stacked bar charts  
21 showing the relative abundance (%) of the bacterial genera that present statistically significant  
22 differences between age groups in mild (a), moderate (b), and severe (c) COVID-19 patients.  
23 Bacterial genera are arranged in alphabetical order.

24

25

26 **Supplementary figure legends**

27 **Figure S1. Comparison of alpha diversity parameters across the age and COVID-19 disease**  
28 **severity groups studied.** Box-whisker plots showing the alpha diversity inverse Simpson index

1 values for the age groups without any prior stratification by COVID-19 disease severity (**a**), for  
2 the disease severity groups without any prior stratification by age (**b**), for the age groups within  
3 each of the disease severity groups (**c**), and for the disease severity groups within each of the age  
4 groups (**d**). Each sample is represented by one dot. The Wilcoxon signed-rank test was used to  
5 determine statistical significance ( $p$ -value  $< 0.05$ ) in the comparisons between the different groups,  
6 and, for clarity, only the statistically significant differences and their  $p$ -values are showed in the  
7 graphs (**a-d**). The age group A1 includes subjects between 1 and 20 years old, A2 between 21 and  
8 40, A3 between 41 and 50, A4 between 51 and 60, A5 between 61 and 70, and A6 includes  
9 individuals over 70 years of age (Table S1).

10

11 **Figure S2. Relative abundance of bacterial genera in the different age and COVID-19**  
12 **severity groups.** Heatmaps showing the abundance for each of the age and severity groups  
13 established for this study of the 57 bacterial genera whose relative abundance is above 1% in at  
14 least one of the age groups. Data are showed in two different ways to facilitate the visualization  
15 and interpretation of such a complex data set: divided first by severity group and then by age group  
16 within each severity group (**a**), and divided first by age group and then by severity group within  
17 each age group (**b**). Data are shown on a linear scale to facilitate the visualization of differences  
18 when abundance is high. Bacterial genera are arranged in decreasing order of abundance  
19 considering the first column on the left, which corresponds to the uninfected control subjects of  
20 the age group A1.

21

22

23

24

25

26

27

## 1 **References**

- 2 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with  
3 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
- 4 2. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation  
5 and intervention. *Nat Rev Immunol*. 2020;20(6):363-74.
- 6 3. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*. 2020;91(1):157-60.
- 7 4. Soheili M, Khateri S, Moradpour F, Mohammadzede P, Zareie M, Mortazavi SMM, et al. The  
8 efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis. *Ann*  
9 *Clin Microbiol Antimicrob*. 2023;22(1):42.
- 10 5. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19  
11 vaccines: a literature review and meta-analysis. *Int J Infect Dis*. 2022;114:252-60.
- 12 6. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older  
13 people? *Aging (Albany NY)*. 2020;12(10):9959-81.
- 14 7. Sahin-Yilmaz A, Naclerio RM. Anatomy and physiology of the upper airway. *Proc Am Thorac Soc*.  
15 2011;8(1):31-9.
- 16 8. Zhou Y, O'Leary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial  
17 detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-analysis. *PLoS One*.  
18 2021;16(7):e0254559.
- 19 9. Wang H, Liu Q, Hu J, Zhou M, Yu MQ, Li KY, et al. Nasopharyngeal Swabs Are More Sensitive Than  
20 Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load. *Front Med*  
21 (Lausanne). 2020;7:334.
- 22 10. Hitzenbichler F, Bauernfeind S, Salzberger B, Schmidt B, Wenzel JJ. Comparison of Throat  
23 Washings, Nasopharyngeal Swabs and Oropharyngeal Swabs for Detection of SARS-CoV-2. *Viruses*.  
24 2021;13(4).
- 25 11. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with  
26 a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3.
- 27 12. Consortium HMP. Structure, function and diversity of the healthy human microbiome. *Nature*.  
28 2012;486(7402):207-14.
- 29 13. Dubourg G, Edouard S, Raoult D. Relationship between nasopharyngeal microbiota and patient's  
30 susceptibility to viral infection. *Expert Rev Anti Infect Ther*. 2019;17(6):437-47.
- 31 14. Candel S, Tyrkalska SD, Álvarez-Santacruz C, Mulero V. The nasopharyngeal microbiome in COVID-  
32 19. *Emerg Microbes Infect*. 2023;12(1):e2165970.
- 33 15. Panebianco C, Latiano T, Paziienza V. Microbiota Manipulation by Probiotics Administration as  
34 Emerging Tool in Cancer Prevention and Therapy. *Front Oncol*. 2020;10:679.
- 35 16. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on  
36 inflammation, obesity, and metabolic disease. *Genome Med*. 2016;8(1):42.
- 37 17. Li N, Ma WT, Pang M, Fan QL, Hua JL. The Commensal Microbiota and Viral Infection: A  
38 Comprehensive Review. *Front Immunol*. 2019;10:1551.
- 39 18. Candel S, Tyrkalska SD, Pérez-Sanz F, Moreno-Docón A, Esteban Á, Cayuela ML, et al. Analysis of  
40 16S rRNA Gene Sequence of Nasopharyngeal Exudate Reveals Changes in Key Microbial Communities  
41 Associated with Aging. *Int J Mol Sci*. 2023;24(4).
- 42 19. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics  
43 of microbiome census data. *PLoS One*. 2013;8(4):e61217.
- 44 20. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq  
45 data with DESeq2. *Genome Biol*. 2014;15(12):550.
- 46 21. Ondov BD, Bergman NH, Phillippy AM. Interactive metagenomic visualization in a Web browser.  
47 *BMC Bioinformatics*. 2011;12:385.



- 1 22. H W. ggplot2: Elegant Graphics for Data Analysis. New York, NY, USA: Springer; 2016.
- 2 23. Gower J. Some distance properties of latent root and vector methods used in multivariate  
3 analysis. *Biometrika*. 1966;53(3-4):325–38.
- 4 24. Lemon KP, Armitage GC, Relman DA, Fischbach MA. Microbiota-targeted therapies: an ecological  
5 perspective. *Sci Transl Med*. 2012;4(137):137rv5.
- 6 25. Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: Vulnerability,  
7 immunity and intervention. *Ageing Res Rev*. 2021;65:101205.
- 8 26. Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the  
9 microbiota and the endocrine system. *FEMS Microbiol Rev*. 2015;39(4):509-21.
- 10 27. He S, Li H, Yu Z, Zhang F, Liang S, Liu H, et al. The Gut Microbiome and Sex Hormone-Related  
11 Diseases. *Front Microbiol*. 2021;12:711137.
- 12 28. De Maio F, Posteraro B, Ponziani FR, Cattani P, Gasbarrini A, Sanguinetti M. Nasopharyngeal  
13 Microbiota Profiling of SARS-CoV-2 Infected Patients. *Biol Proced Online*. 2020;22:18.
- 14 29. Braun T, Halevi S, Hadar R, Efroni G, Glick Saar E, Keller N, et al. SARS-CoV-2 does not have a strong  
15 effect on the nasopharyngeal microbial composition. *Sci Rep*. 2021;11(1):8922.
- 16 30. Nardelli C, Gentile I, Setaro M, Di Domenico C, Pinchera B, Buonomo AR, et al. Nasopharyngeal  
17 Microbiome Signature in COVID-19 Positive Patients: Can We Definitely Get a Role to. *Front Cell Infect*  
18 *Microbiol*. 2021;11:625581.
- 19 31. Engen PA, Naqib A, Jennings C, Green SJ, Landay A, Keshavarzian A, et al. Nasopharyngeal  
20 Microbiota in SARS-CoV-2 Positive and Negative Patients. *Biol Proced Online*. 2021;23(1):10.
- 21 32. Nagy-Szakal D, Couto-Rodriguez M, Wells HL, Barrows JE, Debieu M, Butcher K, et al. Targeted  
22 Hybridization Capture of SARS-CoV-2 and Metagenomics Enables Genetic Variant Discovery and Nasal  
23 Microbiome Insights. *Microbiol Spectr*. 2021;9(2):e0019721.
- 24 33. Gupta A, Karyakarte R, Joshi S, Das R, Jani K, Shouche Y, et al. Nasopharyngeal microbiome reveals  
25 the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with  
26 host types. *Microbes Infect*. 2022;24(1):104880.
- 27 34. Gauthier NPG, Locher K, MacDonald C, Chorlton SD, Charles M, Manges AR. Alterations in the  
28 nasopharyngeal microbiome associated with SARS-CoV-2 infection status and disease severity. *PLoS One*.  
29 2022;17(10):e0275815.
- 30 35. Zhang H, Ai JW, Yang W, Zhou X, He F, Xie S, et al. Metatranscriptomic Characterization of  
31 Coronavirus Disease 2019 Identified a Host Transcriptional Classifier Associated With Immune Signaling.  
32 *Clin Infect Dis*. 2021;73(3):376-85.
- 33 36. Bai X, Narayanan A, Skagerberg M, Ceña-Diez R, Giske CG, Strålin K, et al. Characterization of the  
34 Upper Respiratory Bacterial Microbiome in Critically Ill COVID-19 Patients. *Biomedicines*. 2022;10(5).
- 35 37. Mostafa HH, Fissel JA, Fanelli B, Bergman Y, Gniazdowski V, Dadlani M, et al. Metagenomic Next-  
36 Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19  
37 Patients. *mBio*. 2020;11(6).
- 38 38. Ventero MP, Moreno-Perez O, Molina-Pardines C, Paytuví-Gallart A, Boix V, Escribano I, et al.  
39 Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients. *J Infect*.  
40 2022;84(3):329-36.
- 41 39. Qin T, Wang Y, Deng J, Xu B, Zhu X, Wang J, et al. Super Dominant Pathobiontic Bacteria in the  
42 Nasopharyngeal Microbiota Cause Secondary Bacterial Infection in COVID-19 Patients. *Microbiol Spectr*.  
43 2022;10(3):e0195621.
- 44 40. Chen J, Liu X, Liu W, Yang C, Jia R, Ke Y, et al. Comparison of the respiratory tract microbiome in  
45 hospitalized COVID-19 patients with different disease severity. *J Med Virol*. 2022;94(11):5284-93.
- 46 41. Crovetto F, Selma-Royo M, Crispi F, Carbonetto B, Pascal R, Larroya M, et al. Nasopharyngeal  
47 microbiota profiling of pregnant women with SARS-CoV-2 infection. *Sci Rep*. 2022;12(1):13404.















- 1 42. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition,  
2 variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci U S A*.  
3 2011;108 Suppl 1(Suppl 1):4586-91.
- 4 43. Leite G, Pimentel M, Barlow GM, Chang C, Hosseini A, Wang J, et al. Age and the aging process  
5 significantly alter the small bowel microbiome. *Cell Rep*. 2021;36(13):109765.
- 6 44. Young RB, Marcelino VR, Chonwerawong M, Gulliver EL, Forster SC. Key Technologies for  
7 Progressing Discovery of Microbiome-Based Medicines. *Front Microbiol*. 2021;12:685935.
- 8 45. Jian W, Dong X. Transfer of *Bifidobacterium inopinatum* and *Bifidobacterium denticolens* to  
9 *Scardovia inopinata* gen. nov., comb. nov., and *Parascardovia denticolens* gen. nov., comb. nov.,  
10 respectively. *Int J Syst Evol Microbiol*. 2002;52(Pt 3):809-12.
- 11 46. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu WH, et al. The human oral microbiome. *J*  
12 *Bacteriol*. 2010;192(19):5002-17.
- 13 47. Tanner AC, Mathney JM, Kent RL, Chalmers NI, Hughes CV, Loo CY, et al. Cultivable anaerobic  
14 microbiota of severe early childhood caries. *J Clin Microbiol*. 2011;49(4):1464-74.
- 15 48. Isaac RD, Sanjeev K, Subbulakshmi CL, Amirtharaj LV, Sekar M. Identification of a novel bacterium.  
16 *J Conserv Dent*. 2022;25(3):297-305.
- 17 49. Rueca M, Fontana A, Bartolini B, Piselli P, Mazzarelli A, Copetti M, et al. Investigation of  
18 Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing. *Int J Environ*  
19 *Res Public Health*. 2021;18(4).
- 20 50. De Boeck I, Wittouck S, Wuyts S, Oerlemans EFM, van den Broek MFL, Vandenheuvel D, et al.  
21 Comparing the Healthy Nose and Nasopharynx Microbiota Reveals Continuity As Well As Niche-Specificity.  
22 *Front Microbiol*. 2017;8:2372.
- 23 51. Tyrkalska SD, Martínez-López A, Arroyo AB, Martínez-Morcillo FJ, Candel S, García-Moreno D, et  
24 al. Differential proinflammatory activities of Spike proteins of SARS-CoV-2 variants of concern. *Sci Adv*.  
25 2022;8(37):eabo0732.
- 26 52. Panebianco C, Andriulli A, Paziienza V. Pharmacomicrobiomics: exploiting the drug-microbiota  
27 interactions in anticancer therapies. *Microbiome*. 2018;6(1):92.

28

# Figure 1














# Figure 2



medRxiv preprint doi: <https://doi.org/10.1101/2023.12.20.23300278>; this version posted December 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

# Figure 3




COVID-19 severity

bioRxiv preprint doi: <https://doi.org/10.1101/2023.12.20.23300278>; this version posted December 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



# Figure 4

## a COVID-19 severity group




medRxiv preprint doi: <https://doi.org/10.1101/2023.12.20.23300278>; this version posted December 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

## b Age group




# Figure 5

a




b



# Figure 6


## a

### Mild COVID-19




## b

### Moderate COVID-19






## c

### Severe COVID-19



# Figure S1






# Figure S2

## a COVID-19 severity group



medRxiv preprint doi: <https://doi.org/10.1101/2023.12.20.23300278>; this version posted December 22, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

## b Age group



**Table S1.** Nasopharyngeal exudate samples collected for this study

Age group	Sex	Uninfected control individuals	COVID-19 patients		
			Mild severity	Moderate severity	Severe severity
A1: 1-20 years	<i>Female</i>	10	9	0	0
	<i>Male</i>	9	10	0	0
A2: 21-40 years	<i>Female</i>	10	10	10	5
	<i>Male</i>	10	9	10	4
A3: 41-50 years	<i>Female</i>	9	10	10	0
	<i>Male</i>	10	10	9	10
A4: 51-60 years	<i>Female</i>	10	10	10	5
	<i>Male</i>	10	10	10	8
A5: 61-70 years	<i>Female</i>	10	10	8	7
	<i>Male</i>	10	9	10	7
A6: >70 years	<i>Female</i>	9	10	10	9
	<i>Male</i>	10	9	10	10
Total	<i>Female</i>	58	59	48	26
	<i>Male</i>	59	57	49	39

**Table S2.** Statistical analysis of the PCoA results for all the possible comparisons between age or COVID-19 disease severity groups as indicated, according to the nonparametric statistical test ANOSIM. The statistically significant differences (p-value < 0.05) are highlighted in bold letter, and their p-values are marked with an asterisk. C, control; Mi, mild; Mo, moderate; S, severe.

Figure	COVID-19 severity / Age group	Groups compared	R statistic	p-value
2a	All severities	A1 vs A2	0.0225403302442818	0.172
		A1 vs A3	0.00985368634997909	0.323
		<b>A1 vs A4</b>	<b>0.0696035169824357</b>	<b>0.026*</b>
		<b>A1 vs A5</b>	<b>0.0682091293053175</b>	<b>0.025*</b>
		<b>A1 vs A6</b>	<b>0.0958548202968153</b>	<b>0.01*</b>
		A2 vs A3	0.00212237712313652	0.322
		A2 vs A4	0.00417321880195379	0.236
		<b>A2 vs A5</b>	<b>0.0244457196551504</b>	<b>0.022*</b>
		<b>A2 vs A6</b>	<b>0.0524314610198772</b>	<b>0.003*</b>
		A3 vs A4	0.0134176014306677	0.07
		A3 vs A5	0.00620427310003706	0.207
		<b>A3 vs A6</b>	<b>0.0383097652449282</b>	<b>0.009*</b>
		A4 vs A5	0.0105291264423829	0.102
		<b>A4 vs A6</b>	<b>0.0246515635301208</b>	<b>0.009*</b>
A5 vs A6	0.0105178034825779	0.112		
2b	All ages	<b>C vs Mi</b>	<b>0.403525715495251</b>	<b>0.001*</b>
		<b>C vs Mo</b>	<b>0.336451451199612</b>	<b>0.001*</b>
		<b>C vs S</b>	<b>0.223482775840096</b>	<b>0.001*</b>
		<b>Mi vs Mo</b>	<b>0.08199555505866</b>	<b>0.001*</b>
		<b>Mi vs S</b>	<b>0.0976108525956802</b>	<b>0.002*</b>
		<b>Mo vs S</b>	<b>0.0521428060149072</b>	<b>0.01*</b>
Figure	COVID-19 severity group	Age groups compared	R statistic	p-value
2c	Mild	A1 vs A2	0.0126678654160794	0.268
		A1 vs A3	0.0042280215774894	0.357
		<b>A1 vs A4</b>	<b>0.0715993585070709</b>	<b>0.026*</b>
		<b>A1 vs A5</b>	<b>0.0706614180881567</b>	<b>0.024*</b>
		A1 vs A6	0.0310054915682559	0.14
		A2 vs A3	0.0435923604023909	0.1
		<b>A2 vs A4</b>	<b>0.11188219857122</b>	<b>0.012*</b>
		A2 vs A5	0.0700620433817692	0.056
		A2 vs A6	0.0448235084479434	0.114
		<b>A3 vs A4</b>	<b>0.0956184210526317</b>	<b>0.019*</b>
		A3 vs A5	0.0143461145939641	0.236

Figure	Age group	COVID-19 severity groups compared	R statistic	p-value
2c	Moderate	A3 vs A4	0.0536229771103659	0.066
		<b>A4 vs A5</b>	<b>0.147805802595131</b>	<b>0.002*</b>
		A4 vs A6	0.0409680711473976	0.111
		<b>A5 vs A6</b>	<b>0.109086196562505</b>	<b>0.015*</b>
		<b>A2 vs A3</b>	<b>0.111065753025222</b>	<b>0.016*</b>
		A2 vs A4	0.000986842105263227	0.321
		<b>A2 vs A5</b>	<b>0.242646582442501</b>	<b>0.001*</b>
		<b>A2 vs A6</b>	<b>0.297605263157895</b>	<b>0.001*</b>
		A3 vs A4	0.0400933080623998	0.106
		A3 vs A5	0.0301783264746229	0.127
		<b>A3 vs A6</b>	<b>0.0807406327452982</b>	<b>0.007*</b>
		<b>A4 vs A5</b>	<b>0.16504697116942</b>	<b>0.002*</b>
		<b>A4 vs A6</b>	<b>0.166855263157895</b>	<b>0.001*</b>
2c	Severe	A2 vs A3	-0.0224965706447187	0.533
		A2 vs A4	0.0257909731593942	0.28
		A2 vs A5	-0.0421197350331208	0.692
		A2 vs A6	0.0615588891713987	0.173
		<b>A3 vs A4</b>	<b>0.117948717948718</b>	<b>0.043*</b>
		A3 vs A5	-0.0110294117647059	0.469
		A3 vs A6	0.134746588693957	0.069
		A4 vs A5	-0.0602119773717407	0.982
		A4 vs A6	-0.0030730208282523	0.446
		A5 vs A6	-0.005108190323136	0.414
2d	A1	<b>C vs Mi</b>	<b>0.519981856765644</b>	<b>0.001*</b>
2d	A2	<b>C vs Mi</b>	<b>0.601691208630996</b>	<b>0.001*</b>
		<b>C vs Mo</b>	<b>0.5065</b>	<b>0.001*</b>
		<b>C vs S</b>	<b>0.269960668633235</b>	<b>0.004*</b>
		<b>Mi vs Mo</b>	<b>0.330485493512174</b>	<b>0.001*</b>
		<b>Mi vs S</b>	<b>0.332994321552674</b>	<b>0.003*</b>
		<b>Mo vs S</b>	<b>0.205113077679449</b>	<b>0.01*</b>
2d	A3	<b>C vs Mi</b>	<b>0.328969237498178</b>	<b>0.001*</b>
		<b>C vs Mo</b>	<b>0.509711490175115</b>	<b>0.001*</b>
		C vs S	0.121296296296296	0.056
		<b>Mi vs Mo</b>	<b>0.0703163726490742</b>	<b>0.025*</b>
		Mi vs S	0.0186382978723404	0.335
		<b>Mo vs S</b>	<b>0.268908382066277</b>	<b>0.007*</b>
2d	A4	<b>C vs Mi</b>	<b>0.455736842105263</b>	<b>0.001*</b>
		<b>C vs Mo</b>	<b>0.358052631578947</b>	<b>0.001*</b>
		<b>C vs S</b>	<b>0.228386911595867</b>	<b>0.003*</b>
		<b>Mi vs Mo</b>	<b>0.209934210526316</b>	<b>0.001*</b>
		<b>Mi vs S</b>	<b>0.129764638346728</b>	<b>0.03*</b>
		Mo vs S	0.0866819747416764	0.069

		It is made available under a <a href="https://creativecommons.org/licenses/by-nc/4.0/">CC-BY-NC-ND 4.0 International license</a> .		
2d	A5	<b>C vs Mi</b>	<b>0.285420615250037</b>	<b>0.001*</b>
		<b>C vs Mo</b>	<b>0.245286686103013</b>	<b>0.001*</b>
		<b>C vs S</b>	<b>0.114972038637519</b>	<b>0.024*</b>
		<b>Mi vs Mo</b>	<b>0.10571438885279</b>	<b>0.007*</b>
		<b>Mi vs S</b>	<b>0.131033691097974</b>	<b>0.026*</b>
		Mo vs S	0.0298920114493885	0.232
2d	A6	<b>C vs Mi</b>	<b>0.350634203236623</b>	<b>0.001*</b>
		<b>C vs Mo</b>	<b>0.292579093162268</b>	<b>0.001*</b>
		<b>C vs S</b>	<b>0.213425993423078</b>	<b>0.004*</b>
		Mi vs Mo	0.0229187928269428	0.173
		Mi vs S	0.0215612901135572	0.181
		Mo vs S	0.0142149001312144	0.235

**Table S3.** Summary of the statistical analysis of the relative abundance differences between the age groups established in this study for mild, moderate, and severe COVID-19 patients, as indicated. Only the statistically significant differences (adjusted p-value < 0.05) are shown.

## MILD COVID-19 SEVERITY

Genus	baseMean	log2FoldChange	lfcSE	stat	p-value	Adjusted p-value	Age groups compared
<i>Acinetobacter</i>	15127,961	1,753	0,578	3,035	0,002	0,048	A4_A5
<i>Actinomyces</i>	398,074	2,29	0,853	2,683	0,007	0,036	A2_A6
<i>Alloprevotella</i>	187,097	3,231	1,059	3,053	0,002	0,015	A2_A6
		3,496	1,045	3,344	0,001	0,006	A4_A6
		2,702	1,059	2,552	0,011	0,048	A5_A6
<i>Bifidobacterium</i>	16,556	4,71	1,426	3,303	0,001	0,013	A1_A5
		3,934	1,388	2,834	0,005	0,031	A2_A4
		5,55	1,424	3,896	0	0,001	A2_A5
		-4,963	1,427	-3,479	0,001	0,004	A5_A6
<i>Bosea</i>	401,565	-2,873	0,997	-2,883	0,004	0,026	A1_A4
		-3,084	0,997	-3,095	0,002	0,016	A2_A4
		3,343	0,997	3,353	0,001	0,006	A4_A6
<i>Brevundimonas</i>	5060,261	2,3	0,639	3,6	0	0,003	A3_A6
		2,645	0,647	4,088	0	0	A5_A6
<i>Bulleidia</i>	6,264	5,172	1,636	3,16	0,002	0,016	A1_A4
		4,922	1,648	2,987	0,003	0,023	A1_A5
		5,175	1,675	3,089	0,002	0,013	A1_A6
		4,262	1,676	2,543	0,011	0,045	A2_A6
<i>Burkholderia</i>	62,377	20,588	2,715	7,582	0	0	A1_A6
		21,654	2,711	7,987	0	0	A2_A6
		26,799	2,676	10,016	0	0	A3_A6
		24,401	2,676	9,119	0	0	A4_A6
		21,061	2,714	7,761	0	0	A5_A6
<i>Capnocytophaga</i>	86,147	-4,642	1,551	-2,992	0,003	0,023	A1_A5
<i>Corynebacterium</i>	92,239	-4,113	1,184	-3,474	0,001	0,005	A2_A4
		-4,238	1,199	-3,535	0	0,004	A2_A5
		-3,04	1,2	-2,534	0,011	0,045	A2_A6
<i>Dolosigranulum</i>	51,792	23,977	1,997	12,005	0	0	A1_A2
		-21,122	1,984	-10,645	0	0	A2_A3
		-25,587	1,972	-12,974	0	0	A2_A4
		-24,081	1,997	-12,057	0	0	A2_A5
		-27,439	1,996	-13,75	0	0	A2_A6
		-6,317	1,929	-3,275	0,001	0,008	A3_A6
<i>Leptotrichia</i>	224,389	2,873	1,148	2,503	0,012	0,045	A2_A6
<i>Moraxella</i>	130,937	6,35	1,538	4,13	0	0,001	A1_A2

		4,618	1,515	3,047	0,002	0,018	A1_A4
		5,548	1,539	3,606	0	0,002	A1_A6
<i>Porphyromonas</i>	475,245	2,47	0,712	3,468	0,001	0,006	A4_A6
		1,911	0,721	2,649	0,008	0,044	A5_A6
<i>Prevotella</i>	5394,065	1,457	0,524	2,781	0,005	0,031	A2_A6
<i>Pseudomonas</i>	14997,008	-2,841	0,691	-4,112	0	0,002	A1_A3
		-2,026	0,7	-2,896	0,004	0,025	A1_A5
		2,529	0,682	3,709	0	0,008	A3_A4
		2,65	0,691	3,835	0	0,002	A3_A6
		1,835	0,7	2,623	0,009	0,044	A5_A6
<i>Pseudoxanthomonas</i>	348,769	7,303	2,4	3,043	0,002	0,015	A4_A6
<i>Ralstonia</i>	8,671	22,523	2,143	10,51	0	0	A1_A6
		20,518	2,147	9,555	0	0	A2_A6
		23,15	2,117	10,937	0	0	A3_A6
		19,258	2,133	9,03	0	0	A4_A6
		20,319	2,15	9,452	0	0	A5_A6
<i>Rothia</i>	147,817	-3,176	1,094	-2,902	0,004	0,025	A3_A6
<i>Sphingobacterium</i>	14,4	-15,84	4,853	-3,264	0,001	0,022	A1_A3
		-24,17	4,834	-5	0	0	A1_A4
		-20,282	4,9	-4,14	0	0	A1_A6
		-25,575	4,853	-5,27	0	0	A2_A3
		-33,905	4,834	-7,013	0	0	A2_A4
		-30,016	4,9	-6,126	0	0	A2_A6
		25,192	4,853	5,191	0	0	A3_A5
		33,522	4,834	6,934	0	0	A4_A5
-29,633	4,9	-6,048	0	0	A5_A6		
<i>Sphingomonas</i>	975,21	5,627	1,114	5,052	0	0	A1_A4
		5,147	1,128	4,564	0	0	A1_A5
		4,115	1,128	3,649	0	0,002	A1_A6
		5,265	1,114	4,726	0	0	A2_A4
		4,785	1,128	4,243	0	0	A2_A5
		3,753	1,128	3,328	0,001	0,007	A2_A6
<i>Staphylococcus</i>	104,676	3,362	1,12	3,002	0,003	0,036	A1_A2
		3,957	1,107	3,574	0	0,005	A1_A4



		5,28	1,127	4,687	0	0	A1_A5
		4,465	1,113	4,013	0	0,001	A3_A5
		-3,167	1,128	-2,809	0,005	0,033	A5_A6
<i>Stenotrophomonas</i>	291,969	-2,472	0,936	-2,641	0,008	0,047	A1_A4
		2,538	0,936	2,71	0,007	0,037	A4_A6
<b>MODERATE COVID-19 SEVERITY</b>							
<b>Genus</b>	<b>baseMean</b>	<b>log2FoldChange</b>	<b>lfcSE</b>	<b>stat</b>	<b>p-value</b>	<b>Adjusted p-value</b>	<b>Age groups compared</b>
<i>Alcaligenes</i>	395,263	7,3	1,439	5,074	0	0	A2_A5
		8,774	1,417	6,191	0	0	A2_A6
		4,515	1,457	3,099	0,002	0,028	A3_A5
		5,989	1,436	4,172	0	0	A3_A6
		8,715	1,439	6,058	0	0	A4_A5
		10,189	1,417	7,19	0	0	A4_A6
<i>Alloprevotella</i>	242,803	6,103	1,768	3,451	0,001	0,002	A2_A6
		5,379	1,791	3,003	0,003	0,013	A3_A6
		5,358	1,768	3,03	0,002	0,018	A4_A6
<i>Cetobacterium</i>	0,934	-20,683	4,518	-4,577	0	0	A2_A6
		-27,986	4,578	-6,113	0	0	A3_A6
		-28,371	4,519	-6,279	0	0	A4_A6
		-27,685	4,644	-5,962	0	0	A5_A6
<i>Corynebacterium</i>	846,952	-3,07	1,089	-2,819	0,005	0,045	A3_A5
		-3,329	1,061	-3,138	0,002	0,01	A3_A6
		-3,004	1,047	-2,87	0,004	0,025	A4_A6
<i>Dolosigranulum</i>	126,882	-6,144	2,214	-2,775	0,006	0,018	A2_A6
		-6,454	2,31	-2,794	0,005	0,045	A3_A5
		-7,031	2,25	-3,125	0,002	0,01	A3_A6
		-5,775	2,212	-2,61	0,009	0,049	A4_A6
<i>Gemella</i>	123,606	-3,695	1,317	-2,806	0,005	0,018	A2_A6
<i>Granulicatella</i>	273,24	-3,311	0,871	-3,799	0	0,001	A2_A6
		-2,614	0,883	-2,962	0,003	0,013	A3_A6
<i>Haemophilus</i>	644,243	3,895	1,217	3,199	0,001	0,015	A4_A5

<i>Porphyromonas</i>	579,685	-4,086	1,18	-3,464	0,001	0,002	A2_A6
		-4,363	1,212	-3,601	0	0,005	A5_A6
<i>Pseudoxanthomonas</i>	27,197	-23,363	3,569	-6,547	0	0	A2_A4
		-21,488	3,665	-5,862	0	0	A2_A5
		-23,397	3,568	-6,557	0	0	A2_A6
		-33,474	3,616	-9,257	0	0	A3_A4
		-31,598	3,712	-8,513	0	0	A3_A5
		-33,507	3,616	-9,267	0	0	A3_A6
<i>Rothia</i>	732,239	-3,995	1,024	-3,903	0	0,002	A2_A4
		-4,276	1,024	-4,178	0	0	A2_A6
<i>Serratia</i>	13831,693	5,5	0,897	6,128	0	0	A2_A5
		8,049	0,874	9,207	0	0	A2_A6
		5,314	0,909	5,849	0	0	A3_A5
		7,863	0,886	8,879	0	0	A3_A6
		6,583	0,897	7,335	0	0	A4_A5
		9,132	0,874	10,446	0	0	A4_A6
		2,549	0,898	2,838	0,005	0,049	A5_A6
<i>Sphingobacterium</i>	5,88	-23,834	4,517	-5,277	0	0	A2_A6
		-26,488	4,576	-5,788	0	0	A3_A6
		-26,58	4,517	-5,885	0	0	A4_A6
		-26,432	4,642	-5,695	0	0	A5_A6
<i>Sphingomonas</i>	930,798	-2,85	0,929	-3,067	0,002	0,023	A2_A5
		-4,278	0,904	-4,73	0	0	A2_A6
		-3,282	0,916	-3,583	0	0,002	A3_A6
		-3,366	0,929	-3,622	0	0,004	A4_A5
		-4,794	0,905	-5,3	0	0	A4_A6
<i>Streptococcus</i>	5556,438	-1,891	0,559	-3,38	0,001	0,01	A2_A4
		-2,473	0,559	-4,421	0	0	A2_A6
<b>SEVERE COVID-19 SEVERITY</b>							
<b>Genus</b>	<b>baseMean</b>	<b>log2FoldChange</b>	<b>lfcSE</b>	<b>stat</b>	<b>p-value</b>	<b>Adjusted p-value</b>	<b>Age groups compared</b>

<i>Dolosigranulum</i>	551,807	-24,649	5,387	-4,576	0	0	A2_A3
		-17,892	5,093	-3,513	0	0,01	A2_A4
		-26,027	5,015	-5,189	0	0	A2_A5
		-26,194	4,755	-5,508	0	0	A2_A6
<i>Moraxella</i>	31,491	24,709	5,075	4,868	0	0	A2_A4
		19,502	4,941	3,947	0	0,003	A3_A4
		-25,688	4,516	-5,689	0	0	A4_A5
		-16,415	4,25	-3,862	0	0,005	A4_A6
<i>Mycoplasma</i>	17,595	9,358	2,561	3,655	0	0,006	A4_A5
<i>Shuttleworthia</i>	41,453	-19,204	5,39	-3,563	0	0,008	A2_A3
		-16,963	5,099	-3,327	0,001	0,013	A2_A4
		-23,964	5,016	-4,778	0	0	A2_A5
		-16,521	4,768	-3,465	0,001	0,011	A2_A6